Renormalization of Coulomb interactions in s-wave superconductor Nax_xCoO2_2

We study the renormalized Coulomb interactions due to retardation effect in Na$_x$CoO$_2$. Although the Morel-Anderson's pseudo potential for $a_{1g}$ orbital $\mu^*_{a1g}$ is relatively large because the direct Coulomb repulsion $U$ is large, that for interband transition between $a_{1g}$ and $e_g'$ orbitals $\mu^*_{a1g,eg'}$ is very small since the renormalization factor for pair hopping $J$ is square of that for $U$. Therefore, the s-wave superconductivity due to valence-band Suhl-Kondo mechanism will survive against strong Coulomb interactions. The interband hopping of Cooper pairs due to shear phonons is essential to understand the superconductivity in Na$_x$CoO$_2$.Comment: 2pages, 2figures, Proceedings of ICM in Kyoto, 200

Application of Optimal Control to CPMG Refocusing Pulse Design

We apply optimal control theory (OCT) to the design of refocusing pulses suitable for the CPMG sequence that are robust over a wide range of B0 and B1 offsets. We also introduce a model, based on recent progress in the analysis of unitary dynamics in the field of quantum information processing (QIP), that describes the multiple refocusing dynamics of the CPMG sequence as a dephasing Pauli channel. This model provides a compact characterization of the consequences and severity of residual pulse errors. We illustrate the methods by considering a specific example of designing and analyzing broadband OCT refocusing pulses of length 10 t180 that are constrained by the maximum instantaneous pulse power. We show that with this refocusing pulse, the CPMG sequence can refocus over 98% of magnetization for resonance offsets up to 3.2 times the maximum RF amplitude, even in the presence of +/- 10% RF inhomogeneity.Comment: 23 pages, 10 figures; Revised and reformatted version with new title and significant changes to Introduction and Conclusions section

Myasthenia gravis

Myasthenia gravis (MG) is a rare, autoimmune neuromuscular junction disorder. Contemporary prevalence rates approach 1/5,000. MG presents with painless, fluctuating, fatigable weakness involving specific muscle groups. Ocular weakness with asymmetric ptosis and binocular diplopia is the most typical initial presentation, while early or isolated oropharyngeal or limb weakness is less common. The course is variable, and most patients with initial ocular weakness develop bulbar or limb weakness within three years of initial symptom onset. MG results from antibody-mediated, T cell-dependent immunologic attack on the endplate region of the postsynaptic membrane. In patients with fatigable muscle weakness, the diagnosis of MG is supported by: 1. pharmacologic testing with edrophonium chloride that elicits unequivocal improvement in strength; 2. electrophysiologic testing with repetitive nerve stimulation (RNS) studies and/or single-fiber electromyography (SFEMG) that demonstrates a primary postsynaptic neuromuscular junctional disorder; and 3. serologic demonstration of acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) antibodies. Differential diagnosis includes congenital myasthenic syndromes, Lambert Eaton syndrome, botulism, organophosphate intoxication, mitochondrial disorders involving progressive external ophthalmoplegia, acute inflammatory demyelinating polyradiculoneuropathy (AIDP), motor neuron disease, and brainstem ischemia. Treatment must be individualized, and may include symptomatic treatment with cholinesterase inhibitors and immune modulation with corticosteroids, azathioprine, cyclosporine, and mycophenolate mofetil. Rapid, temporary improvement may be achieved for myasthenic crises and exacerbations with plasma exchange (PEX) or intravenous immunoglobulin (IVIg). Owing to improved diagnostic testing, immunotherapy, and intensive care, the contemporary prognosis is favorable with less than five percent mortality and nearly normal life expectancy

Understanding American Power:Conceptual clarity, strategic priorities and the decline debate

What does it mean for the United States to be powerful? The prospect of a decline in American power, especially relative to a rising China, has attracted considerable scholarly and political attention. Despite a wealth of data, disagreements persist regarding both the likely trajectory of the US-China balance and the most effective strategy for preserving America’s advantage into the future. This article locates the source of these enduring disputes in fundamental conceptual differences over the meaning of power itself. We map the distinct tracks of argument within the decline debate, showing that competing positions are often rooted in differences of focus rather than disputes over fact. Most fundamental is a divide between analyses dedicated to national capabilities, and others that emphasise mechanisms of relational power. This divide underpins how strategists think about the goal of preserving or extending American power. We therefore construct a typology of competing understandings of what it means for America to be powerful, to show that a strategy suited to bolstering American power according to one definition of that goal may not support, and may even undermine, American power understood in other ways